Oncopeptides AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	83.24	71.12	31.65	35.22	8.36	118.3
Revenue Growth (YoY)	108.91%	124.72%	-10.14%	321.54%	-92.94%	-
Cost of Revenue	2.86	2.45	2.66	-1.08	0.01	53.12
Gross Profit	80.38	68.67	28.99	36.3	8.35	65.17
Selling, General & Admin	193.6	194.62	197.28	188.48	142.2	873.81
Research & Development	95.74	102.97	121.19	106.95	217.66	679.93
Other Operating Expenses	-5.62	-3.29	-6.9	-6.34	-4.57	3.9
Operating Expenses	283.71	294.31	311.57	289.09	355.29	1,558
Operating Income	-203.34	-225.64	-282.59	-252.79	-346.94	-1,492
Interest Expense	-14.45	-14.45	-12.66	-5.79	-0.88	-0.95
Interest & Investment Income	1.95	1.95	8.2	8.59	2.62	0.49
Currency Exchange Gain (Loss)	3.01	3.01	-1.82	1.54	8.96	71.54
Other Non Operating Income (Expenses)	-6.07	-12.33	4.66	-	-	0
EBT Excluding Unusual Items	-218.9	-247.46	-284.21	-248.45	-336.24	-1,421
Gain (Loss) on Sale of Investments	-0.71	-0.71	-	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	-	-1.44	-
Pretax Income	-219.61	-248.17	-284.21	-248.45	-337.68	-1,421
Income Tax Expense	1.49	1.42	0.4	0.66	0.27	8.95
Net Income	-221.1	-249.59	-284.61	-249.11	-337.95	-1,430
Net Income to Common	-221.1	-249.59	-284.61	-249.11	-337.95	-1,430
Shares Outstanding (Basic)	-	227	166	90	82	75
Shares Outstanding (Diluted)	-	227	166	90	82	75
Shares Change (YoY)	-	36.37%	84.14%	9.80%	9.33%	20.72%
EPS (Basic)	-	-1.10	-1.71	-2.76	-4.11	-19.00
EPS (Diluted)	-	-1.10	-1.71	-2.76	-4.11	-19.00
Free Cash Flow	-200.16	-222.88	-260.93	-279.61	-423.02	-1,517
Free Cash Flow Per Share	-	-0.98	-1.57	-3.09	-5.14	-20.14
Gross Margin	96.57%	96.55%	91.59%	103.06%	99.93%	55.09%
Operating Margin	-244.29%	-317.27%	-892.91%	-717.74%	-4152.44%	-1261.64%
Profit Margin	-265.64%	-350.94%	-899.29%	-707.30%	-4044.90%	-1209.11%
Free Cash Flow Margin	-240.47%	-313.40%	-824.47%	-793.89%	-5063.03%	-1282.16%
EBITDA	-201.11	-223.36	-280.12	-250.35	-344.93	-1,491
D&A For EBITDA	2.23	2.28	2.47	2.44	2.01	1.72
EBIT	-203.34	-225.64	-282.59	-252.79	-346.94	-1,492

Source: S&P Global Market Intelligence. Standard template. Financial Sources.